Authors: Acharya J, Lyon C, Bottomley DM
Erlotinib, a specific epidermal growth factor receptor tyrosine kinase inhibitor, is used to treat various metastatic cancers. It is known to cause an acneiform rash. Herein, we report a case where the rash spared the previous radiotherapy field. A limitation of this study is that it is an anecdotal case report. Further research into the pathologic process of the rash is warranted to understand the reason for its absence in the irradiated skin.
PMID: 19103369 [PubMed - in process] (Source: Journal of the American Academy of Dermatology)

Related posts

• Preconference galore (0)
• Fellowships for aspiring law professors (updated september 2008) (0)
• Delayed diagnosis of brain tumor in a patient with flexor spasms and spastic foot drop (0)
• [commentary] the molecular ancestry of segmentation mechanisms (0)
• Little strokes, big trouble and more… (0)

Tags: Academy, Late, report, study

This entry was posted on czwartek, grudzień 25th, 2008 at 8:19 przed południem and is filed under Medical Academies. You can follow any responses to this entry through the RSS 2.0 feed. You can skip to the end and leave a response. Pinging is currently not allowed.